Mouse anti-Aggrus monoclonal antibodies
US8980264B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Mar 9, 2012 |
| Grant date | Mar 17, 2015 |
| Priority date | — |
| Expiry date | Mar 9, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/34
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a monoclonal antibody or a functional fragment thereof, capable of recognizing Aggrus epitope that includes an amino-acid sequence represented by a sequence ID 1, 3, or 4, and the monoclonal antibody or the functional fragment thereof produced from a hybridoma with accession number of FERM BP-11446, FERM BP-11447, FERM BP-11448 or FERM BP-11449. The present invention provides the hybridoma, and further an Aggrus-CLEC-2 binding inhibitor and a pharmaceutical composition for inhibition of platelet aggregation, prevention of cancer metastasis, or treatment of tumor or cancer, including the monoclonal antibody or the functional fragment thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.